From rxpgnews.com
Single Infusion of Zoledronic Acid More Effective in Pagets Disease
By Novartis,
Sep 8, 2005 - 1:07:38 AM
Pagets disease is the second most prevalent bone disease after osteoporosis. Affecting more than one million people, the chronic bone disorder is marked by the malfunction of the bodys regular bone building process and may result in pain, deformities and fractures.
This pooled analysis of two identical double-blind, active-controlled studies compared a single 15-minute infusion of zoledronic acid 5 mg solution to oral risedronate (30 mg per day for 60 days) in 357 patients with Pagets disease. At six months, nearly all patients receiving one dose of zoledronic acid 5 mg solution were effectively treated. Specifically, 96 percent of patients treated with zoledronic acid 5 mg solution responded compared to 74 percent of patients who received risedronate (p<0<0<0
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )